During the last session, Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s traded shares were 0.89 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $7.33, reflecting an intraday gain of 2.09% or $0.15. The 52-week high for the DNA share is $75.20, that puts it down -925.92 from that peak though still a striking 28.24% gain since the share price plummeted to a 52-week low of $5.26. The company’s market capitalization is $385.41M, and the average intraday trading volume over the past 10 days was 0.83 million shares, and the average trade volume was 1.49 million shares over the past three months.
Ginkgo Bioworks Holdings Inc (DNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.83. DNA has a Sell rating from 2 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.82.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Ginkgo Bioworks Holdings Inc (DNA) registered a 2.09% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.09% in intraday trading to $7.33, hitting a weekly high. The stock’s 5-day price performance is -12.00%, and it has moved by 16.91% in 30 days. Based on these gigs, the overall price performance for the year is -89.53%. The short interest in Ginkgo Bioworks Holdings Inc (NYSE:DNA) is 8.19 million shares and it means that shorts have 4.48 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.5, which implies a decrease of -12.77% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.35 and $12 respectively. As a result, DNA is trading at a discount of -63.71% off the target high and 40.65% off the low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Statistics show that Ginkgo Bioworks Holdings Inc has outperformed its competitors in share price, compared to the industry in which it operates. Ginkgo Bioworks Holdings Inc (DNA) shares have gone down -81.86% during the last six months, with a year-to-date growth rate more than the industry average at 19.23% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 55.90% this quarter and then jump 44.50% in the quarter after that. In the rating firms’ projections, revenue will decrease -26.10% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 45M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 47.94M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 55.43M and 34.76M respectively. In this case, analysts expect current quarter sales to shrink by -18.80% and then jump by 37.90% in the coming quarter.
While earnings are projected to return 41.34% in 2024, the next five years will return 31.20% per annum.
DNA Dividends
Ginkgo Bioworks Holdings Inc is due to release its next quarterly earnings on 2024-Aug-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
Ginkgo Bioworks Holdings Inc insiders own 6.43% of total outstanding shares while institutional holders control 63.76%, with the float percentage being 68.14%. VIKING GLOBAL INVESTORS LP is the largest shareholder of the company, while 376.0 institutions own stock in it. As of 2024-06-30, the company held over 143.09 million shares (or 7.1383% of all shares), a total value of $47.83 million in shares.
The next largest institutional holding, with 138.96 million shares, is of VANGUARD GROUP INC’s that is approximately 6.9327% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $46.46 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ginkgo Bioworks Holdings Inc (DNA) shares are Vanguard Small-Cap Index Fund and Vanguard Total Stock Market Index Fund . Data provided on Jun 30, 2024 indicates that Vanguard Small-Cap Index Fund owns about 967.13 shares. This amounts to just over 0.06 percent of the company’s overall shares, with a $7.09 million market value. The same data shows that the other fund manager holds slightly less at 1.12, or about 0.06% of the stock, which is worth about $8.21 million.
